Expand ALKS Menu
ALKS MENU

ALKS Latest Press Releases

-- August 24, 2026 --

The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 Business Wire 6:30 PM

-- July 28, 2026 --

Alkermes plc Reports Second Quarter 2026 Financial Results Business Wire 7:00 AM

-- July 14, 2026 --

Alkermes to Report Second Quarter Financial Results on July 28, 2026 Business Wire 4:00 PM

-- July 13, 2026 --

Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis Business Wire 7:00 AM

-- June 17, 2026 --

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 Business Wire 4:15 PM

-- June 15, 2026 --

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe Business Wire 7:00 AM

-- June 4, 2026 --

Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research Business Wire 7:00 AM

-- June 3, 2026 --

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 4:05 PM

-- May 26, 2026 --

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting Business Wire 7:00 AM

-- May 21, 2026 --

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences Business Wire 7:00 AM

-- May 12, 2026 --

Alkermes Announces Positive Topline Results From REVITALYZ? Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia Business Wire 7:00 AM

-- May 5, 2026 --

Alkermes plc Reports First Quarter 2026 Financial Results Business Wire 7:00 AM

-- April 21, 2026 --

Alkermes to Report First Quarter Financial Results on May 5, 2026 Business Wire 4:05 PM

-- April 16, 2026 --

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting Business Wire 7:00 AM

-- April 14, 2026 --

Findings From Long-Term Analysis of the Effects of LYBALVI (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry Business Wire 7:00 AM

-- April 1, 2026 --

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 Business Wire 7:00 AM
Market Data Delayed 15 Minutes